发作性睡病市场-全球行业规模、份额、趋势、机遇和预测，2018-2028 年，按类型、诊断、治疗、最终用户、地区和竞争进行分析

在预测期内，全球发作性睡病市场预计将实现显着增长。 这是由于该地区用于治疗睡眠障碍的医疗保健行业的投资数量和规模不断增加。 此外，由于压力大的生活方式导致睡眠呼吸暂停和失眠等神经系统疾病的患病率增加，预计这些年来将推动市场增长。 同样，根据临床试验，大公司正在投资开发低成本的发作性睡病治疗方法，预计这将在预测期内进一步推动市场增长。 政府，针对发作性睡病药物发现了 131 项试验。 其中，发作性睡病类药物可供18至55岁的男女服用。 此外，发作性睡病诊断技术的显着改进以及製药公司开发具有长期益处和减少副作用的变体将进一步增加对发作性睡病的需求，推动市场增长到 2028 年。预计。 此外，越来越多的市场参与者专注于为用户的利益开发新药和治疗方法，预计也将增加对发作性睡病的需求并支持市场的增长。 根据疾病预防控制中心的数据，到 2020 年，34.8% 的美国人口将患有发作性睡病或睡眠障碍。

发作性睡病患病率上升

我们预测，压力大的生活方式、遗传缺陷、青春期和更年期期间发生的荷尔蒙变化以及睡眠模式的剧烈变化将增加发作性睡病的严重程度和患病率。它一直是推动这一时期市场增长的主要因素。 此外，发作性睡病药物还可用于治疗睡眠呼吸暂停、失眠和不宁腿综合征，进一步推动市场增长。 发作性睡病患病率上升和肥胖人口增加是整个预测期内发作性睡病市场增长的主要驱动力。 莫达非尼在患者治疗中的使用也刺激了市场扩张，因为它的副作用比其他兴奋剂少。 因此，适当的治疗将有助于预防此类疾病，这有望推动全球发作性睡病市场。 据估计，有 1-4% 的儿童患有睡眠呼吸暂停症，其中大多数年龄在 2-8 岁之间。

增加特定机构的举措

在预测期内，人们对发作性睡病治疗的认识不断提高，预计将产生显着增长。 此外，莫达非尼用于治疗副作用较少的患者，有助于预防此类疾病，在预测期内引领发作性睡病市场。 印度和南非等国家的政府机构正在开展运动，向人们和医护人员宣传嗜睡症药物和嗜睡症治疗的好处，不仅在发展中地区，而且在农村地区，这将在预测期内促进市场增长. 预计。 根据 2021 年 11 月更新的国家神经疾病和中风研究所情况说明书，发作性睡病影响了美国 135,000 至 200,000 人。 多年来，预计美国对发作性睡病药物开发的资金增加将进一步推动市场增长。 此外，在预测期内，快速采用嗜睡症药物的新疗法有望推动市场增长。 此外，美国非营利组织 Project Sleep 发起了一个名为“发作性睡病的崛起之声”的计划，向当地社区发送文本和声音，以提高认识并减少对其他患有发作性睡病的人的社会耻辱感。我们鼓励他们分享他们的故事通过与他们交谈。

近期发展

• 2021 年 12 月，Rygand Pharmaceuticals, Inc. 宣布扩大其子公司 Icagen 和 GSK 之间的现有合作和许可协议。底部。 此次扩张将利用 Icagen 基于离子通道的发现技术和针对跨膜蛋白的小分子疗法的独特专业知识。 这项新协议建立在 2020 年 12 月的初步协议基础上，旨在识别和开发与神经系统疾病相关的特定基因验证分子靶标的抑製剂。
• 2020 年 1 月 Adair Pharmaceuticals, Inc. 和 NLS Pharmaceuticals Limited 宣布 Mazindol CR 候选产品用于治疗发作性睡病和注意力缺陷多动障碍 (ADHD)，同意共同开发

可自定义

根据市场数据，TechSci Research 根据公司的具体需求提供定制服务。 该报告可以定制为：

公司信息

• 对其他市场参与者（最多 5 家公司）进行深入分析和概况分析

内容

第 1 章概述

• 市场定义
• 市场范围
  • 目标市场
  • 研究目标年份
  • 主要市场细分

第二章研究方法论

• 调查目的
• 基线调查方法
• 主要行业合作伙伴
• 主要协会和次要信息
• 调查方法
• 数据三角测量和验证
• 假设和限制

第 3 章执行摘要

• 市场概览
• 主要市场细分概述
• 主要市场参与者概览
• 主要地区/国家概览
• 市场驱动因素、挑战和趋势

第 4 章 VOC（客户之声）

第5章临床试验分析

• 正在进行的临床试验
• 完成临床试验
• 已完成临床试验
• 管道细分（按开发阶段）
• 管道细分（按状态
• 管道细分（按研究类型）
• 按地区划分的渠道细分
• 临床试验热图

第 6 章嗜睡症全球市场展望

• 市场规模和预测
  • 按金额
• 市场份额和预测
  • 按类型（类型 1、类型 2、其他）
  • 通过诊断（多导睡眠图、多次睡眠潜伏期测试等）
  • 通过治疗药物（兴奋剂、抗抑郁药、羟丁酸钠等）
  • 最终用户（医院、诊所、零售药店等）
  • 按公司分类（2022 年）
• 产品地图
  • 按类型
  • 通过诊断
  • 通过治疗
  • 最终用户

第 7 章北美髮作性睡病市场展望

• 市场规模和预测
  • 按金额
• 市场份额和预测
  • 按类型（类型 1、类型 2、其他）
  • 通过诊断（多导睡眠图、多次睡眠潜伏期测试等）
  • 通过治疗药物（兴奋剂、抗抑郁药、羟丁酸钠等）
  • 最终用户（医院、诊所、零售药店等）
  • 按国家
• 北美：国家/地区分析
  • 美国
  • 加拿大
  • 墨西哥

第 8 章欧洲发作性睡病市场展望

• 市场规模和预测
  • 按金额
• 市场份额和预测
  • 按类型（类型 1、类型 2、其他）
  • 通过诊断（多导睡眠图、多次睡眠潜伏期测试等）
  • 通过治疗药物（兴奋剂、抗抑郁药、羟丁酸钠等）
  • 最终用户（医院、诊所、零售药店等）
  • 按国家
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 意大利
  • 西班牙

第 9 章亚太嗜睡症市场展望

• 市场规模和预测
  • 按金额
• 市场份额和预测
  • 按类型（类型 1、类型 2、其他）
  • 通过诊断（多导睡眠图、多次睡眠潜伏期测试等）
  • 通过治疗药物（兴奋剂、抗抑郁药、羟丁酸钠等）
  • 最终用户（医院、诊所、零售药店等）
  • 按国家
• 亚太地区：国家/地区分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳大利亚

第 10 章南美髮作性睡病市场展望

• 市场规模和预测
  • 按金额
• 市场份额和预测
  • 按类型（类型 1、类型 2、其他）
  • 通过诊断（多导睡眠图、多次睡眠潜伏期测试等）
  • 通过治疗药物（兴奋剂、抗抑郁药、羟丁酸钠等）
  • 最终用户（医院、诊所、零售药店等）
  • 按国家
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 11 章中东和非洲发作性睡病市场展望

• 市场规模和预测
  • 按金额
• 市场份额和预测
  • 按类型（类型 1、类型 2、其他）
  • 通过诊断（多导睡眠图、多次睡眠潜伏期测试等）
  • 通过治疗药物（兴奋剂、抗抑郁药、羟丁酸钠等）
  • 最终用户（医院、诊所、零售药店等）
  • 按国家
• MEA：国家分析
  • 南非发作性睡病
  • 沙特阿拉伯发作性睡病
  • 阿联酋发作性睡病

第 12 章市场动态

• 司机
  • 发作性睡病的患病率越来越高
  • 政府机构加大力度
• 做
  • 关于发作性睡病药物的副作用
  • 与发作性睡病药物相关的误诊

第13章市场趋势与发展

• 近期发展状况
• 併购
• 产品发布

第 14 章全球嗜睡症市场：SWOT 分析

第 15 章波特的五力分析

• 行业竞争
• 新进入的可能性
• 供应商的力量
• 客户力量
• 替代品的威胁

第十六章竞争格局关于

• 业务概览
• 提供的产品
• 近期发展状况
• 财务（据报导）
• 主要人物
• SWOT 分析
  • Jazz Pharmaceuticals Plc.
  • BIOPROJET.
  • Arena Pharmaceuticals, Inc.
  • Graymark Healthcare, Inc.
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG.
  • Shire.
  • Shionogi Inc.
  • Ligand Pharmaceuticals, Inc.

第 17 章战略建议

The global narcolepsy market is anticipated to register an impressive growth rate during the forecast period. This can be ascribed to the rising number and size of investments in the healthcare sector for the treatment of sleep disorders across the region. Additionally, the growing prevalence of neurological disorders such as sleep apnea and insomnia due to stressful lifestyles is expected to drive the growth of the market over the years. Similarly, the major players are investing in the development of narcolepsy drugs at low cost, which is expected to further drive the growth of the market over the forecast period, according to Clinical trials. Gov,131 studies have been found for narcolepsy drugs. Among them, narcolepsy cataplexy-type drugs can be taken by both males and females between 18-55 years of age. Moreover, significant improvements in the diagnostic technologies for narcolepsy and pharmaceutical companies are developing variants with long-term benefits and reduced side which are further expected to increase the demand for narcolepsy, thereby fuelling the market growth through 2028. Furthermore, an increasing number of major players in the market focusing on developing new drugs and therapies for the benefit of users is further expected to increase the demand for narcolepsy, thereby supporting the market growth. According to CDC, in 2020, 34.8 % of people were affected with narcolepsy or sleep disorder among the U.S population.

Growing Prevalence of Narcolepsy

The growing severity of the disease and the growing number of people affected by narcolepsy due to stressful lifestyles, an inherited genetic fault, hormonal changes that take place during puberty or menopause, and a sudden change in sleep patterns are the main factors driving the growth of the market during the forecast period. Moreover, narcolepsy medications can also be used to treat sleep apnea, insomnia, and restless legs syndrome, which will further drive the growth of the market. The major drivers of the narcolepsy market growth throughout the forecast period are rising narcolepsy prevalence and a growing obese population. In addition, because it has fewer adverse effects than other stimulants, the use of modafinil to treat patients is adding to its market expansion. So, proper treatment can aid in the prevention of such ailments, which is expected to drive the global narcolepsy market. It's estimated that 1 to 4% of children suffer from sleep apnea, many of them being between 2 and 8 years old.

Growing Initiatives by Government Organizations

Growing awareness about narcolepsy treatment among the population is expected to create significant growth during the forecast period. Moreover, the use of modafinil to treat patients because it has fewer side effects, and it can help to prevent such disorders, thereby driving the narcolepsy market during the forecast period. Government organizations from different countries, such as India and South Africa, have taken initiatives for campaigns to educate people and health workers about the narcolepsy drug's advantages and narcolepsy treatment in developing as well as rural areas, which is expected to boost market growth during the forecast period. According to the National Institute of Neurological Disorders and Stroke fact sheet updated in November 2021, narcolepsy affects anywhere between 135,000 and 200,000 people in the United States. The rise in donations for the development of narcolepsy treatments in the United States is further anticipated to drive the growth of the market over the years. Moreover, the rapid adoption of a new therapy for the treatment of narcolepsy drugs is anticipated to drive market growth over the forecast period. Furthermore, Project Sleep, a non-profit organization based in the United States, launched a program called "Rising Voices of Narcolepsy" to educate people about narcolepsy to share their stories through writing and verbally addressing local communities to raise awareness and reduce social stigma among others suffering from the disease.

Market Segmentation

The global narcolepsy market can be segmented on the basis of type, diagnosis, treatment, end user, and by region. Based on the type, the market can be segmented into Type 1, Type 2, and Others. Based on the diagnosis, the market can be further divided into polysomnograms, multiple sleep latency tests, and others. On the basis of the treatment, the market can be further split into stimulants, antidepressants, sodium oxybate, and others. Based on end users, the market can be split into hospitals, clinics, retail pharmacies, and others. On the basis of region, North America dominated the market among Asia Pacific, Europe, Middle East & Africa, and South America. Among the different countries, the United States dominated the global narcolepsy market on account of the increasing incidence of sleep disorders in the country.

Recent Developments

• In December 2021, Ligand Pharmaceuticals, Inc. announced the expansion of its existing collaboration and license agreement between its subsidiary, Icagen, and GSK. This expansion will leverage Icagen's ion-channel-based discovery technology and unique expertise in small molecule therapeutics targeting transmembrane proteins. This new agreement builds upon the initial December 2020 agreement to identify and develop inhibitors of a specific genetically-validated molecular target relevant to neurological diseases.

• In January 2020, Adare Pharmaceuticals, Inc. and NLS Pharmaceutics Ltd. collaborated to develop mazindol CR product candidates for the treatment of narcolepsy and Attention Deficit Hyperactivity Disorder (ADHD).

Market Players

Jazz Pharmaceuticals Plc., BIOPROJET., Arena Pharmaceuticals, Inc., Graymark Healthcare, Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., Novartis AG., Shire., Shionogi Inc., Ligand Pharmaceuticals, Inc are some of the leading players operating in the Global Narcolepsy Market.

Report Scope

In this report, the global narcolepsy market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Narcolepsy Market, By Type:

• Type 1
• Type 2
• Others

Narcolepsy Market, By Diagnosis:

• Polysomnogram
• Multiple Sleep Latency Test
• Others

Narcolepsy Market, By Treatment:

• Stimulants
• Antidepressants
• Sodium Oxybate
• Others

Narcolepsy Market, By Route of End User:

• Hospitals
• Clinics
• Retail Pharmacies
• Others

Narcolepsy Market, By Region:

• North America
  • United States
  • Canada
  • Mexico

• Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain

• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia

• South America
  • Brazil
  • Argentina
  • Colombia

• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Narcolepsy Market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

• 5.1. Ongoing Clinical Trials
• 5.2. Completed Clinical Trials
• 5.3. Terminated Clinical Trials
• 5.4. Breakdown of Pipeline, By Development Phase
• 5.5. Breakdown of Pipeline, By Status
• 5.6. Breakdown of Pipeline, By Study Type
• 5.7. Breakdown of Pipeline, By Region
• 5.8. Clinical Trials Heat Map

6. Global Narcolepsy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type (Type 1, Type 2, Others)
  • 6.2.2. By Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)
  • 6.2.3. By Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)
  • 6.2.4. By End User (Hospitals, Clinics, Retail Pharmacies, Others)
  • 6.2.5. By Company (2022)
• 6.3. Product Map
  • 6.3.1 By Type
  • 6.3.2 By Diagnosis
  • 6.3.3 By Treatment
  • 6.3.4 By End User

7. North America Narcolepsy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type (Type 1, Type 2, Others)
  • 7.2.2. By Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)
  • 7.2.3. By Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)
  • 7.2.4. By End User (Hospitals, Clinics, Retail Pharmacies, Others)
  • 7.2.5. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Narcolepsy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Diagnosis
      • 7.3.1.2.3. By Treatment
      • 7.3.1.2.4. By End User
  • 7.3.2. Canada Narcolepsy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Diagnosis
      • 7.3.2.2.3. By Treatment
      • 7.3.2.2.4. By End User
  • 7.3.3. Mexico Narcolepsy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Diagnosis
      • 7.3.3.2.3. By Treatment
      • 7.3.3.2.4. By End User

8. Europe Narcolepsy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type (Type 1, Type 2, Others)
  • 8.2.2. By Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)
  • 8.2.3. By Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)
  • 8.2.4. By End User (Hospitals, Clinics, Retail Pharmacies, Others)
  • 8.2.5. By Country
• 8.3. Europe: Country Analysis
  • 8.3.1. France Narcolepsy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Diagnosis
      • 8.3.1.2.3. By Treatment
      • 8.3.1.2.4. By End User
  • 8.3.2. Germany Narcolepsy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Diagnosis
      • 8.3.2.2.3. By Treatment
      • 8.3.2.2.4. By End User
  • 8.3.3. United Kingdom Narcolepsy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Diagnosis
      • 8.3.3.2.3. By Treatment
      • 8.3.3.2.4. By End User
  • 8.3.4. Italy Narcolepsy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Diagnosis
      • 8.3.4.2.3. By Treatment
      • 8.3.4.2.4. By End User
  • 8.3.5. Spain Narcolepsy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Diagnosis
      • 8.3.5.2.3. By Treatment
      • 8.3.5.2.4. By End User

9. Asia-Pacific Narcolepsy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type (Type 1, Type 2, Others)
  • 9.2.2. By Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)
  • 9.2.3. By Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)
  • 9.2.4. By End User (Hospitals, Clinics, Retail Pharmacies, Others)
  • 9.2.5. By Country
• 9.3. Asia-Pacific: Country Analysis
  • 9.3.1. China Narcolepsy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Diagnosis
      • 9.3.1.2.3. By Treatment
      • 9.3.1.2.4. By End User
  • 9.3.2. India Narcolepsy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Diagnosis
      • 9.3.2.2.3. By Treatment
      • 9.3.2.2.4. By End User
  • 9.3.3. Japan Narcolepsy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Diagnosis
      • 9.3.3.2.3. By Treatment
      • 9.3.3.2.4. By End User
  • 9.3.4. South Korea Narcolepsy Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Type
      • 9.3.4.2.2. By Diagnosis
      • 9.3.4.2.3. By Treatment
      • 9.3.4.2.4. By End User
  • 9.3.5. Australia Narcolepsy Market Outlook
    • 9.3.5.1. Market Size & Forecast
      • 9.3.5.1.1. By Value
    • 9.3.5.2. Market Share & Forecast
      • 9.3.5.2.1. By Type
      • 9.3.5.2.2. By Diagnosis
      • 9.3.5.2.3. By Treatment
      • 9.3.5.2.4. By End User

10. South America Narcolepsy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type (Type 1, Type 2, Others)
  • 10.2.2. By Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)
  • 10.2.3. By Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)
  • 10.2.4. By End User (Hospitals, Clinics, Retail Pharmacies, Others)
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Narcolepsy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Diagnosis
      • 10.3.1.2.3. By Treatment
      • 10.3.1.2.4. By End User
  • 10.3.2. Argentina Narcolepsy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Diagnosis
      • 10.3.2.2.3. By Treatment
      • 10.3.2.2.4. By End User
  • 10.3.3. Colombia Narcolepsy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Diagnosis
      • 10.3.3.2.3. By Treatment
      • 10.3.3.2.4. By End User

11. Middle East and Africa Narcolepsy Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Type (Type 1, Type 2, Others)
  • 11.2.2. By Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)
  • 11.2.3. By Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)
  • 11.2.4. By End User (Hospitals, Clinics, Retail Pharmacies, Others)
  • 11.2.5. By Country
• 11.3. MEA: Country Analysis
  • 11.3.1. South Africa Narcolepsy Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Type
      • 11.3.1.2.2. By Diagnosis
      • 11.3.1.2.3. By Treatment
      • 11.3.1.2.4. By End User
  • 11.3.2. Saudi Arabia Narcolepsy Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Type
      • 11.3.2.2.2. By Diagnosis
      • 11.3.2.2.3. By Treatment
      • 11.3.2.2.4. By End User
  • 11.3.3. UAE Narcolepsy Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By Type
      • 11.3.3.2.2. By Diagnosis
      • 11.3.3.2.3. By Treatment
      • 11.3.3.2.4. By End User

12. Market Dynamics

• 12.1. Drivers
  • 12.1.1 Increase in Prevalence of Narcolepsy
  • 12.1.2 Growing Initiatives by Government Organizations
• 12.2. Challenges
  • 12.2.1 Adverse effect related to narcolepsy drugs.
  • 12.2.2 Misdiagnosis related to narcolepsy treatment

13. Market Trends & Developments

• 13.1. Recent Development
• 13.2. Mergers & Acquisitions
• 13.3. Product Launches

14. Global Narcolepsy Market: SWOT Analysis

15. Porter's Five Forces Analysis

• 15.1. Competition in the Industry
• 15.2. Potential of New Entrants
• 15.3. Power of Suppliers
• 15.4. Power of Customers
• 15.5. Threat of Substitute Products

16. Competitive Landscape

• 16.1. Business Overview
• 16.2. Product Offerings
• 16.3. Recent Developments
• 16.4. Financials (As Reported)
• 16.5. Key Personnel
• 16.6. SWOT Analysis
  • 16.6.1 Jazz Pharmaceuticals Plc.
  • 16.6.2 BIOPROJET.
  • 16.6.3 Arena Pharmaceuticals, Inc.
  • 16.6.4 Graymark Healthcare, Inc.
  • 16.6.5 Mylan N.V.
  • 16.6.6 Teva Pharmaceutical Industries Ltd.
  • 16.6.7 Novartis AG.
  • 16.6.8 Shire.
  • 16.6.9 Shionogi Inc.
  • 16.6.10 Ligand Pharmaceuticals, Inc.

17. Strategic Recommendations